P
Peter Williams
Researcher at Janssen Pharmaceutica
Publications - 24
Citations - 2110
Peter Williams is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Rilpivirine & Cabotegravir. The author has an hindex of 17, co-authored 24 publications receiving 1697 citations.
Papers
More filters
Journal ArticleDOI
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis,Juan González-García,Hans Jürgen Stellbrink,Joseph J. Eron,Yazdan Yazdanpanah,Daniel Podzamczer,Thomas A. Lutz,Jonathan B. Angel,Gary Richmond,Bonaventura Clotet,Félix Gutiérrez,Louis Sloan,Marty St. Clair,Miranda Murray,Susan L. Ford,Joseph M. Mrus,Parul Patel,Herta Crauwels,Sandy Griffith,Kenneth Sutton,David Dorey,Kimberly Y. Smith,Peter Williams,William Spreen +23 more
TL;DR: Both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral comparator group and the primary analysis used a Bayesian approach to evaluate the hypothesis that the proportion with viral suppression for each long- acting regimen is not worse than the oral regimen proportion.
Journal ArticleDOI
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe Orkin,Keikawus Arastéh,Miguel de Górgolas Hernández-Mora,Vadim Pokrovsky,Edgar T. Overton,Pierre-Marie Girard,Shinichi Oka,Sharon Walmsley,Chris Bettacchi,Cynthia Brinson,Patrick Philibert,Johan Lombaard,Marty St. Clair,Herta Crauwels,Susan L. Ford,Parul Patel,Vasiliki Chounta,Ronald D'Amico,Simon Vanveggel,David Dorey,Amy Cutrell,Sandy Griffith,David A. Margolis,Peter Williams,Wim Louis Julien Parys,Kimberly Y. Smith,William Spreen +26 more
TL;DR: Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravIR-abacavir-lamivudine with regard to maintaining HIV-1 suppression.
Journal ArticleDOI
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells,Jaime-Federico Andrade-Villanueva,Gary Richmond,Giuliano Rizzardini,Axel Baumgarten,Mar Masiá,Gulam H Latiff,Vadim Pokrovsky,Fritz Bredeek,Graham H R Smith,Pedro Cahn,Yeon Sook Kim,Susan L. Ford,Christine L. Talarico,Parul Patel,Vasiliki Chounta,Herta Crauwels,Wim Louis Julien Parys,Simon Vanveggel,Joseph M. Mrus,Jenny Huang,Conn M. Harrington,Krischan J Hudson,David A. Margolis,Kimberly Y. Smith,Peter Williams,William Spreen +26 more
TL;DR: In this paper, simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence, which may improve adherence.
Journal ArticleDOI
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
David A. Margolis,Cynthia Brinson,Graham H R Smith,Jerome De Vente,Debbie Hagins,Joseph J. Eron,Sandy Griffith,Marty St. Clair,Marita Stevens,Peter Williams,Susan L. Ford,Britt Stancil,Melinda M Bomar,Krischan J Hudson,Kimberly Y. Smith,William Spreen +15 more
TL;DR: This study assessed cabotegravir plus rilpivirine, as a two-drug oral antiretroviral regimen, for the maintenance of viral suppression in antireTroviral-naive HIV-1-infected individuals.
Journal ArticleDOI
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials
Calvin J. Cohen,Jean-Michel Molina,Pedro Cahn,Bonaventura Clotet,Jan Fourie,Beatriz Grinsztejn,Hao Wu,Margaret A. Johnson,Michael S. Saag,Khuanchai Supparatpinyo,Herta Crauwels,Eric Lefebvre,Laurence T. Rimsky,Simon Vanveggel,Peter Williams,Katia Boven +15 more
TL;DR: Rilpivirine had more virologic failures and improved tolerability versus efavirenz, and development of resistance in both groups; the effects onVirologic failure were more apparent with rilpavirine.